The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

Sarepta already markets three exon-skipping drugs for DMD that have to be taken chronically, but SRP-9001 offers the possibility of a one-shot therapy for the disease. Roche has exclusive rights ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility ...

Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75.

Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...